11-02 : Effects of imidazoline-like drugs on insulin sensitivity and adiponectin pathway

en

27

Issue supplement s1

17

17

2013-04-25

2013-04-25

2013-06

0767-3981

Fundamental and Clinical Pharmacology

INTRODUCTION: Metabolic syndrome is defined as a cluster of cardiovascular and metabolic disorders leading to increased cardiovascular risk. Several investigations showed that sympatho-inhibitory imidazoline-like drugs can improve glucidic and lipid Show moreINTRODUCTION: Metabolic syndrome is defined as a cluster of cardiovascular and metabolic disorders leading to increased cardiovascular risk. Several investigations showed that sympatho-inhibitory imidazoline-like drugs can improve glucidic and lipid metabolism. In addition to their central effects, such drugs may also display peripheral direct metabolic effects. We demonstrated that a selective imidazoline I1 receptor ligand, LNP509, which does not cross the BBB, improves glucose tolerance in aged rats displaying impaired glucose regulation. Our current studies aim at identifying the mechanisms involved in this beneficial metabolic action. CONCLUSION : These data show that an imidazoline I1 receptor selective ligand ameliorates insulin sensitivity of target tissues, thus improving glucose tolerance. How this is causally related to the concomitant stimulation of adiponectin pathway has to be further investigated. The mechanisms involved in the imidazoline-like drugs-induced activation of adiponectin signalling are under investigation. Show less

Wiley

conference publication

C-ACTN

Aucun

Adiponectin ; Imidazoline-like drugs ; Insulino-resistance ; Metabolic syndrome ; Sympatho-inhibition.

aut

Non spécifiée

17th Annual Meeting of French Society of Pharmacology and Therapeutics ; 80th Annual Meeting of Society of Physiology ; 34th Pharmacovigilance Meeting ; 14th APNET Seminar ; 11th CHU CIC Meeting (22–24 April 2013, Angers, France)